Medincell
Uzedy, Teva, and MedinCell’s Collaborative Effort Yields Success in Phase 3 Trials for Long-Acting Schizophrenia Treatment
Uzedy, Teva, MedinCell, long-acting, schizophrenia, phase 3 trials, treatment, collaboration, mental health, neuroscience, psychiatry, injectable medication.
MedinCell and AbbVie Collaborate on Long-Acting Injectable Development with a Potential Value of $1.9 Billion
MedinCell, AbbVie, Long-acting injectable, Development pact, $1.9 billion
AbbVie Secures Deal with Medincell for Long-Acting Injectable Platform, Valued up to $1.9 Billion
AbbVie, Medincell, Long-acting injectable platform, Biotechnology, Deal, $1.9 billion